Our focus is on delivering meaningful patient outcomes by leveraging the untapped potential of continuous delivery and dermal technology.
Continuous delivery platform allows for lower AUC, Cmax, and overall drug exposure.
Potential for improved efficacy and tolerability, and the pursuit of new indications or superiority in existing indications.
Platform Dermal Technology
Our strategic platform provides a controlled, sustained release over multiple days. Starton uses proven transdermal and subcutaneous technologies to transform approved medicines – establishing superiority or new indications.
Starton is focused on flattening the plasma concentration curve to reduce dose-limiting toxicity and deliver improved efficacy.
- Deliver between 50% to 90% lower AUC with equal or better tumor control vs oral
- Avoidance of toxicity due to the lower AUC may allow patients to continue treatment with the avoidance of withdrawals and dose-limiting toxicity, inherently leading to longer progression-free survival (PFS)
- Eliminate periods of subtherapeutic dosing due to short half-life
With each program, we establish an AUC target to identify the blood level (mcg/L) point estimate with oral administration where half of the dose interval is above the point estimate and half of the dose interval is below the point estimate. Using this mid-point method, the total AUC is lower than that observed with oral daily dosing which may reduce the toxicity observed with a higher AUC while maintaining efficacy.
Other active ingredients are being researched at our facility that have not yet been disclosed.
